替拉珠单抗治疗中重度斑块状银屑病:三项随机对照试验第12周和第28周汇总分析
本研究汇总三项随机安慰剂对照试验共2081例中重度斑块状银屑病患者数据,评估替拉珠单抗100mg和200mg的疗效。第12周时替拉珠单抗组PASI 75应答率(100mg组62.3%,200mg组64.8%)显著优于安慰剂组(5.6%,P<0.0001),PASI 90、PASI 100及PGA应答亦显著优于安慰剂。应答率从第12周至第28周持续增加,汇总数据证实替拉珠单抗对中重度斑块状银屑病有效。
要点
- 替拉珠单抗100mg和200mg第12周PASI 75应答率分别为62.3%和64.8%,均显著高于安慰剂5.6%。
- PASI 90、PASI 100及PGA应答在第12周均显著优于安慰剂(P<0.0001)。
- 第12周至第28周应答率持续增加,第8周PASI 50应答可预测PASI 90应答。
核心结论
- 汇总数据证实替拉珠单抗对中重度斑块状银屑病具有显著疗效。
研究设计与样本
- 汇总三项随机安慰剂对照试验数据,共纳入2081例患者,比较替拉珠单抗100mg、200mg与安慰剂组。
主要发现
- 第12周PASI 75应答率:替拉珠单抗100mg组62.3%,200mg组64.8%,安慰剂组5.6%(P<0.0001)。
- 第12周PASI 90、PASI 100及PGA「清除」或「轻微」应答均显著优于安慰剂(P<0.0001)。
- 应答率从第12周至第28周持续增加。
- 第12周替拉珠单抗组PASI和PGA应答在较低体重患者中数值上高于较高体重患者,高体重患者中200mg优于100mg。
- 第12周PASI 75应答在既往使用过生物制剂(55.0%)与未使用过(56.7%)患者间相似;PASI 90、PASI 100及PGA应答在未使用过生物制剂者中通常更高。
临床怎么用
- 替拉珠单抗100mg或200mg可用于中重度斑块状银屑病治疗,高体重患者可能从200mg剂量获益更多。
- 既往生物制剂暴露不影响第12周PASI 75应答,但PASI 90及以上应答在未暴露者中更高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Efficacy of tildrakizumab for plaque psoriasis was demonstrated in randomized, placebo-controlled trials. OBJECTIVE: To consolidate tildrakizumab efficacy results by pooling data. METHODS: Data (N = 2081) from tildrakizumab 100 mg, tildrakizumab 200 mg and placebo groups in three trials were pooled. RESULTS: Proportions of Psoriasis Area and Severity Index (PASI) 75 responders at week 12 were better with tildrakizumab 100 mg (62.3%) and tildrakizumab 200 mg (64.8%) vs. placebo (5.6%; P < 0.0001) and for PASI 90, PASI 100 and Physician's Global Assessment (PGA) 'clear' or 'minimal' vs. placebo (P < 0.0001). Responses increased from weeks 12 to 28. Week 12 PASI and PGA responses to tildrakizumab vs. placebo were numerically greater in patients with lower vs. higher bodyweight and were better with tildrakizumab 200 mg than tildrakizumab 100 mg for patients with higher bodyweight. Week 12 PASI 75 responses vs. placebo with tildrakizumab 100 mg were similar between patients with (55.0%) or without (56.7%) prior biologics. PASI 90, PASI 100 and PGA responses were generally higher in patients without prior biologics. Week 8 PASI 50 response predicted PASI 90 response. CONCLUSION: Pooled data confirmed the efficacy of tildrakizumab for moderate-to-severe plaque psoriasis.
引用
- Papp KA, Reich K, Blauvelt A, et al. Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28. J Eur Acad Dermatol Venereol. 2019. PMID: 30838709. doi:10.1111/jdv.15400
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。